Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
NCT00529503 · Seagen Inc. · PHASE2 · terminated · last registry update 2015-02-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Seagen Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD40 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2016-02-08Also stopped (terminated): Baylor College of Medicine, B-CLL Vaccine + Lenalidomide (NCT01604031)
- 2014-12-23Results posted on the registry: Bio Products Laboratory, Gammaplex (NCT01289847)
- 2014-05-22Also stopped (terminated): University of Southern California, MART-1 antigen + aldesleukin (NCT00006113)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision